German cancer specialists have made significant progress in the development of a vaccine against renal cell carcinoma, with first test results looking promising, it was reported on Monday. The first study of the vaccine was conducted on 19 patients with renal cell carcinoma so advanced that other forms of therapy were no longer effective, with 10 of the patients completing the full series of vaccinations. "Seven of these patients are still alive and have had their disease stabilized for up to 65 weeks," Ingo Schmidt-Wolf of the Center for Integrated Oncology in Bonn, Germany, told the 2012 European Society for Medical Oncology in Vienna. He added that quality of life for the patients improved during the course of the treatment, and that side-effects were relatively minor. For two of the patients, the disease came to a still-stand within 12 weeks, and upon continued administration of the vaccine experienced remission and eventually stabilization. Phase II of the clinical study is currently planned and will be aimed at patients for whom a first or second treatment strategy has lost effectiveness and where the vaccine is a further option.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delays

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor